# Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

> **NCT04567303** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 177 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Zifibancimig
- **DRUG:** Ranibizumab
- **DEVICE:** Port Delivery Platform

## Key facts

- **NCT ID:** NCT04567303
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567303, "Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04567303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*